united therapeutics glp-1 receptor agonist Frontiers Science's 2023 Breakthrough: GLP-1R Agonists
Description
Efficacy and safety of the once-daily GLP-1 receptor agonist lixisenatide in monotherapy: a randomized, double-blind, placebo-controlled trial in patients with type 2 diabetes (GetGoal-Mono)
E.AukrustP.FarupP
10.1002/smll.202408581 Small 46 QianZ.ChenH.XiaM.ChangJ.LiX.YeS.et al (2022)
Following this strategy, different metabolic pathways for carbohydrate, lipid, and protein metabolism could be influenced simultaneously
